An Extension Study of 12 mg Proellex (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Trial Profile

An Extension Study of 12 mg Proellex (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 25 Jul 2017 Status changed from active, no longer recruiting to discontinued due to Business decision.
    • 05 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top